Simon Peter Cooper - 10 Aug 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Medical Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Issuer symbol
KROS
Transactions as of
10 Aug 2021
Net transactions value
$0
Form type
4
Filing time
11 Aug 2021, 16:56:27 UTC
Previous filing
11 Aug 2021
Next filing
25 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Award $0 +60,000 $0.000000 60,000 10 Aug 2021 Common Stock 60,000 $34.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest twenty-five percent (25%) on August 2, 2022, and six and one-quarter percent (6.25%) of such shares shall vest at the end of each successive three (3) month period thereafter, subject to the Reporting Person continuing to provide service through each such date.